trial · primary record
Belzutifan
Advanced Solid Tumors
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2026-11-30 |
| Primary endpoint | maximum tolerated dose (MTD) |
| Registry ID | NCT02974738 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:36.124Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02974738
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.